Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company is focused on the discovery and development of small molecule inhibitors that target metabolic pathways critical to the growth and survival of cancer cells. By disrupting tumor metabolism, Calithera aims to create novel therapeutic options for patients with solid tumors and hematologic malignancies.
The company’s pipeline includes lead candidates such as telaglenastat (CB-839), a glutaminase inhibitor being evaluated in multiple Phase 2 trials across various tumor types, and CB-1158, an arginase inhibitor designed to reprogram the tumor microenvironment and enhance anti-tumor immunity. Calithera also maintains discovery programs exploring additional metabolic targets, leveraging its proprietary chemistry and extensive biomarker capabilities to advance new compounds from preclinical research into the clinic.
Founded in 2008, Calithera completed its initial public offering in 2014 and has since established strategic collaborations with global partners to support clinical development and commercialization. The company operates primarily in the United States but conducts clinical trials and collaborates with research centers in Europe and Asia, reflecting its commitment to developing therapies that can address cancer care needs worldwide.
Calithera’s leadership team combines expertise in oncology drug development, translational biology, and regulatory affairs. The executive management and board members bring experience from both pharmaceutical companies and research institutions, guiding the company’s efforts to translate metabolic insights into innovative treatments for patients battling cancer.
AI Generated. May Contain Errors.
